. 2018 Sep 27;5(11):ofy245. doi: 10.1093/ofid/ofy245

Table 3.

Independent Predictors for Individual DFI-PRRT

	PA^b vs Non-PA, OR (95% CI) (n = 94)	VRE^c vs Non-VRE, OR (95% CI) (n = 52)	3GCE-RE^d vs Non-3GCE-RE, OR (95% CI) (n = 51)
Recent hospitalization	1.50 (0.91–2.46)	3.37 (1.66–6.84)	1.00 (0.46–2.21)
Residence of LTCF	1.11 (0.51–2.41)	^a	3.85 (1.58–9.39)
Peripheral vascular disease	1.68 (0.95–2.96)	17.51 (2.37–129.21)	3.45 (1.29–9.25)
Congestive heart failure	^a	^a	1.31 (0.68–2.52)
Dementia	^a	^a	1.70 (0.68–4.27)
Dependent status (bedridden)	1.74 (0.98–3.09)	^a	1.21 (0.51–2.86)
Prior debridement	^a	0.97 (0.51–1.86)	^a
History of diabetic foot ulcer associated with PA	3.06 (1.14–8.20)	^a	^a
History of diabetic foot ulcer associated with VRE	^a	7.83 (1.82–33.64)	^a
History of diabetic foot ulcer associated with 3GCE-RE	^a	^a	8.95 (0.76–105.60)
Prior BLBLI use	^a	^a	2.69 (1.18–6.15)
Prior cephalosporin, third generation	^a	^a	2.95 (1.11–7.88)
Prior cefepime use	2.41 (1.09–5.34)	^a	3.27 (1.27–8.40)
Prior vancomycin use	^a	1.67 (0.83–3.37)	^a

Abbreviations: 3GCE-RE, third-generation cephalosporin-resistant Enterobacteriaceae; BLBLI, beta-lactam/beta-lactamase inhibitor; DFI, diabetic foot infection; LTCF, long-term care facility; NS, nonsignificant; PA, Pseudomonas aeruginosa; PRRT, pathogens resistant to empiric recommended treatment; VRE, vancomycin-resistant Enterococcus spp.

^aVariables were not included in the model.

^bControlled for LTCF, dependent status, recent hospitalization, chronic kidney disease, peripheral vascular disease, prior quinolone use, history of PA in a diabetic foot ulcer, and prior use of cefepime.

^cControlled for LTCF, chronic kidney disease, prior debridement, and prior vancomycin use.

^dControlled for dependent status, recent hospitalization, congestive heart failure, dementia, and history of 3GCE-RE in a diabetic foot ulcer.